Has Zeeshan Sardar, MD received payments from drug or device companies?

Yes. Drug and device makers reported $216,726 in general payments to Zeeshan Sardar, MD across 214 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Zeeshan Sardar, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Zeeshan Sardar, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Zeeshan Sardar, MD

Orthopaedic Surgery · New York, NYNPI 1205243557

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (34.7%), royalties or licence payments and consulting fees — rather than concentrated in one kind of arrangement. Medtronic accounts for 84.6% of it on its own, with 15 other manufacturers making up the rest. 2025 is the largest year on record at $73,748, 3.5 times the $21,120 reported in 2019. Among orthopaedic surgery clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$216,726in general payments, 2019–2025

Across 214 payments — averaging $1012.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Medtronic$183K
Stryker$12K
Carlsmed, Inc.$7K
Si-bone, Inc.$5K
Amgen$3K
Alphatec Spine, Inc$2K
plus $5K from 10 others

$22,500in research payments, 2019–2025

Across 1 payment — averaging $22,500 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

Amgen$23K

What the payments were for

Royalty or licence$60,27528%
Consulting fees$59,09527%
Speaking & faculty fees$75,09635%
Travel & lodging$14,0256%
Food & beverage$8,0834%
Entertainment$1520%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Medtronic(2 entities)	138	$183,250
Stryker	3	$11,633
Carlsmed, Inc.	1	$7,250
Si-bone, Inc.	15	$4,846
Amgen	3	$2,721
Alphatec Spine, Inc	5	$2,246
Globus Medical(2 entities)	10	$1,753
Smaio SA	4	$985
Zimvie Inc.	7	$809
Arthrex	6	$352
Johnson & Johnson	13	$305
DJO, LLC	2	$252
Kuros Biosciences USA, Inc	1	$152
Medacta USA, Inc.	1	$79
Orthofix Medical, Inc.	4	$58
Surgical Theater. Inc.	1	$35

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

MAZOR X SYSTEM$24,270
CD HORIZON$17,502
PIVOX Oblique Lateral Spinal System$15,539
AVIATOR$11,506
TRITANIUM$11,327
SERRATO$11,200
Adaptix$9,350
CLYDESDALE PTC SPINAL SYSTEM$7,700
aprevo$7,250
CD HORIZON SPINAL SYSTEM$6,828
UNID_PASS$4,466
IFUSE IMPLANT SYSTEM$4,250
Mazor X Stealth Edition$4,025
DIVERGENCE-L$3,241
O-ARM$3,025
CLYDESDALE$2,906
EVENITY$2,620
MazorX - Renaissance$2,475
Other - Miscellaneous$2,246
UNiD$1,238

How this compares

$216,726 in reported general payments places this provider in the 90th percentile of 1,079 orthopaedic surgery providers in New York.

See all orthopaedic surgery providers in New York →

Medicare billing

Part B allowed, 2024

$200,782

Medicare patients

200

Services billed

530

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Gabapentin	31	$388
Methylprednisolone	19	$167
Oxycodone Hcl	22	$164
Tramadol Hcl	14	$31

Paid to pharmacies, not to this prescriber.

Other orthopaedic surgery in New York

Anthony RomeoNew York$26.8M
Lawrence LenkeNew York$26.8M
Edwin SuNew York$13.2M
William RicciNew York$11.6M
Steven HaasNew York$11.3M
Giles ScuderiNew York$10.7M
Joseph ZuckermanNew York$9.9M
Evan FlatowNew York$9.6M
Bradford ParsonsNew York$9.4M
Geoffrey WestrichNew York$7.1M

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →